Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

CALT

Calliditas Therapeutics AB (CALT)

Calliditas Therapeutics AB
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CALT
DateTimeSourceHeadlineSymbolCompany
28/05/202422:46PR Newswire (US)Calliditas Therapeutics Presents Data at the 61st European Renal Association CongressNASDAQ:CALTCalliditas Therapeutics AB
28/05/202422:36PR Newswire (US)Calliditas Therapeutics Presents Data at the 61st European Renal Association CongressNASDAQ:CALTCalliditas Therapeutics AB
28/05/202422:28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
28/05/202422:09Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:CALTCalliditas Therapeutics AB
28/05/202417:17PR Newswire (US)Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationNASDAQ:CALTCalliditas Therapeutics AB
28/05/202417:14PR Newswire (US)Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationNASDAQ:CALTCalliditas Therapeutics AB
24/05/202406:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
23/05/202415:55PR Newswire (US)Calliditas Q1 report, January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
23/05/202415:52PR Newswire (US)Calliditas Q1 report, January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
17/05/202406:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
16/05/202416:45PR Newswire (US)Invitation to the presentation of CalliditasĀ“s interim report January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
16/05/202416:43PR Newswire (US)Invitation to the presentation of CalliditasĀ“s interim report January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
15/05/202422:30PR Newswire (US)Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmNASDAQ:CALTCalliditas Therapeutics AB
15/05/202422:24PR Newswire (US)Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmNASDAQ:CALTCalliditas Therapeutics AB
15/05/202421:36PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
15/05/202421:30PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
14/05/202421:52PR Newswire (US)Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaNASDAQ:CALTCalliditas Therapeutics AB
14/05/202421:35PR Newswire (US)Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaNASDAQ:CALTCalliditas Therapeutics AB
06/05/202416:16PR Newswire (US)Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibNASDAQ:CALTCalliditas Therapeutics AB
06/05/202416:11PR Newswire (US)Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibNASDAQ:CALTCalliditas Therapeutics AB
25/04/202403:35PR Newswire (US)Calliditas Therapeutics' 2023 Annual Report PublishedNASDAQ:CALTCalliditas Therapeutics AB
25/04/202403:26PR Newswire (US)Calliditas Therapeutics' 2023 Annual Report PublishedNASDAQ:CALTCalliditas Therapeutics AB
24/04/202417:30PR Newswire (US)Calliditas Announces Positive NefIgArd Open Label Extension ResultsNASDAQ:CALTCalliditas Therapeutics AB
24/04/202417:26PR Newswire (US)Calliditas Announces Positive NefIgArd Open Label Extension ResultsNASDAQ:CALTCalliditas Therapeutics AB
18/04/202421:13PR Newswire (US)Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024NASDAQ:CALTCalliditas Therapeutics AB
18/04/202421:10PR Newswire (US)Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024NASDAQ:CALTCalliditas Therapeutics AB
09/04/202421:24PR Newswire (US)Calliditas Therapeutics to Attend Conferences in AprilNASDAQ:CALTCalliditas Therapeutics AB
09/04/202421:22PR Newswire (US)Calliditas Therapeutics to Attend Conferences in AprilNASDAQ:CALTCalliditas Therapeutics AB
08/04/202422:38PR Newswire (US)Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresNASDAQ:CALTCalliditas Therapeutics AB
08/04/202422:32PR Newswire (US)Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresNASDAQ:CALTCalliditas Therapeutics AB
 Showing the most relevant articles for your search:NASDAQ:CALT